<DOC>
	<DOCNO>NCT02224079</DOCNO>
	<brief_summary>Study ass safety , tolerability pharmacokinetics ( PK ) single intravenous ( i.v . ) dose BIIB 722 CL</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Single Rising Doses BIIB 722 CL HPÎ²CD Young Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male 21 50 year age Broca index &gt; = 20 % &lt; = +20 % Written inform consent accord Good Clinical Practice ( GCP ) local legislation Any finding medical examination ( include blood pressure , pulse rate Electrocardiogram ( ECG ) ) deviate normal clinical relevance History current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic hormonal disorder Diseases central nervous system psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month less ten halflives respective drug enrolment study Use drug , might influence result trial within two week prior administration trial Participation another trial investigational drug ( &lt; = two month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke study day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation ( &gt; = 100 mL within four week prior administration trial ) Excessive physical activity ( within last week study ) Any laboratory value outside reference range clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>